DN2M » Parkinson's disease

Parkinson's disease

Parkinson's disease is the most common neurodegenerative disease after Alzheimer's disease. The number of patients in the North of France (Région Nord-Pas de Calais) is estimated between 6500 and 9000. The symptoms are mainly, but not exclusively, due to the loss of the dopaminergic neurons of the substantia nigra pars compacta, a small mesencephalic nucleus, leading to a dysfunction of the nigrostriatal dopaminergic pathway. Symptomatic treatments are based on dopaminergic drugs: levodopa, dopamine agonists and dopamine metabolism modulators, associated with other modes of treatment (physiotherapy, speech therapy etc.). In advanced stages, some patients are treated by continuous dopaminergic stimulation (subcutaneous apomorphine pump, intraduodenal levodopa infusion) or by the subthalamic nucleus stimulation.

At the Lille University medical center, two teams devote their research to Parkinson's disease in order to elucidate the predisposing factors (INSERM U837, Team 6, led by Prof. A. Destée) and to enhance the knowledge of the dopaminergic and non dopaminergic pathophysiology of the disease (EA 4559, Team 2, Prof. K. Dujardin, L. Defebvre, P. Derambure).


Indirect measure of the iron content in the substantia nigra of a patient with Parkinson’s disease
by R2* MRI sequence (3 Teslas)

Indirect measure of the iron content in the substantia nigra in a mice model of Parkinson’s disease (intoxicated by MPTP)
by R2* MRI sequence (7 Teslas)